Jean J Zhao

List of Publications by Year
in descending order

103 papers	12,906 citations	43973 48 h-index	34900 98 g-index
110 all docs	110 docs citations	110 times ranked	21111 citing authors

#	Article	IF	Citations
1	Blocking PI3K p110Î² Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Molecular Cancer Research, 2022, 20, 673-685.	1.5	6
2	Sarm1 activation produces cADPR to increase intra-axonal Ca++ and promote axon degeneration in PIPN. Journal of Cell Biology, 2022, 221, .	2.3	44
3	Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology, 2022, 24, 316-326.	4.6	34
4	p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nature Communications, 2022, 13, 1473.	5.8	10
5	Targeting CDK4 and CDK6 in cancer. Nature Reviews Cancer, 2022, 22, 356-372.	12.8	125
6	Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake. Cell Reports, 2022, 38, 110509.	2.9	5
7	Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids. Nano Letters, 2022, 22, 4058-4066.	4.5	8
8	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications, 2022, 13, .	5.8	68
9	Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	14
10	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer, 2021, 2, 34-48.	5.7	48
11	The role of the PIK3CA gene in the development and aging of the brain. Scientific Reports, 2021, 11, 291.	1.6	3
12	Lacrimal gland budding requires PI3K-dependent suppression of EGF signaling. Science Advances, 2021, 7, .	4.7	2
13	Disrupted PI3K subunit p110Î± signaling protects against pulmonary hypertension and reverses established disease in rodents. Journal of Clinical Investigation, 2021, 131, .	3.9	12
14	How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic Resistance in Cancer. Cancer Research, 2021, 81, 6074-6077.	0.4	16
15	Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene, 2020, 39, 50-63.	2.6	43
16	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii9-ii9.	0.4	0
17	Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Reports, 2020, 32, 108196.	2.9	13
18	PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-Î± inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24427-24433.	3.3	12

#	Article	IF	Citations
19	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discovery, 2020, 10, 1352-1373.	7.7	145
20	Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Science Advances, 2020, 6, eabb2210.	4.7	46
21	High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Science Signaling, 2020, 13, .	1.6	44
22	Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications. Clinical Cancer Research, 2020, 26, 5557-5566.	3.2	25
23	A sequential methodology for the rapid identification and characterization of breast cancer-associated functional SNPs. Nature Communications, 2020, 11, 3340.	5.8	17
24	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii228-ii228.	0.6	0
25	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology, 2019, 37, 741-750.	0.8	103
26	Improving orthotopic mouse models of patient-derived breast cancer brain metastases by aÂmodified intracarotid injectionÂmethodÂ. Scientific Reports, 2019, 9, 622.	1.6	20
27	Targeted Profiling of RNA Translation. Current Protocols in Molecular Biology, 2019, 125, e71.	2.9	4
28	PI3K alpha and delta promote hematopoietic stem cell activation. JCI Insight, 2019, 4, .	2.3	31
29	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell, 2018, 33, 173-186.e5.	7.7	201
30	Oncogenic Kinaseâ€“Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stemâ€“like Cells. Cancer Research, 2018, 78, 2248-2261.	0.4	66
31	Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?. Clinical Cancer Research, 2018, 24, 1795-1804.	3.2	67
32	Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. Journal of Clinical Oncology, 2018, 36, 1339-1342.	0.8	11
33	PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Reports, 2018, 25, 2972-2980.e5.	2.9	381
34	BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1Î± activation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9600-E9609.	3.3	20
35	A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. IScience, 2018, 9, 149-160.	1.9	12
36	Structure-Based Drug Design and Identification of H₂O-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo. Journal of Medicinal Chemistry, 2018, 61, 8613-8624.	2.9	27

#	Article	IF	Citations
37	Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9325-E9332.	3.3	28
38	Dual HDAC and PI3K Inhibition Abrogates NFÎºB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Research, 2018, 78, 4007-4021.	0.4	60
39	CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends in Cell Biology, 2018, 28, 911-925.	3.6	273
40	Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget, 2018, 9, 23878-23889.	0.8	11
41	Pik3ca is required for mouse uterine gland development and pregnancy. PLoS ONE, 2018, 13, e0191433.	1.1	8
42	An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. ELife, 2018, 7, .	2.8	91
43	PI3Kinase Alpha and Delta Promote Hematopoietic Stem Activation Under Stress. Blood, 2018, 132, 329-329.	0.6	0
44	Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell, 2017, 31, 576-590.e8.	7.7	84
45	PI3K-p110Î± mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85Î±. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7095-7100.	3.3	75
46	The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 123-131.	3.3	117
47	Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature, 2017, 549, 533-537.	13.7	350
48	CRKL Mediates p110Î²-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Reports, 2017, 20, 549-557.	2.9	33
49	CDK4/6 inhibition triggers anti-tumour immunity. Nature, 2017, 548, 471-475.	13.7	998
50	Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro-Oncology, 2017, 19, 22-30.	0.6	32
51	MELK is not necessary for the proliferation of basal-like breast cancer cells. ELife, 2017, 6, .	2.8	86
52	PI3KÎ± inactivation in leptin receptor cells increases leptin sensitivity but disrupts growth and reproduction. JCI Insight, 2017, 2, .	2.3	21
53	Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-Î´/Î³ Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 908-912.	1.3	15
54	Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9810-9815.	3.3	66

#	Article	IF	Citations
55	Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecologic Oncology, 2016, 142, 548-556.	0.6	80
56	PI3K in the ventromedial hypothalamic nucleus mediates estrogenic actions on energy expenditure in female mice. Scientific Reports, 2016, 6, 23459.	1.6	32
57	NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3Kâ€“AKT and JAKâ€“STAT3 pathways. Cell Discovery, 2016, 2, 16030.	3.1	17
58	Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13156-13161.	3.3	12
59	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine, 2016, 22, 723-726.	15.2	105
60	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Reports, 2016, 15, 2692-2704.	2.9	92
61	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell, 2016, 29, 255-269.	7.7	356
62	Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget, 2016, 7, 13153-13166.	0.8	66
63	CDK4/6 inhibition: the late harvest cycle begins. Oncotarget, 2016, 7, 48854-48856.	0.8	4
64	Rac1-mediated membrane raft localization of PI3K/p110Î² is required for its activation by GPCRs or PTEN loss. ELife, 2016, 5, .	2.8	25
65	Measurement of PIP3 Levels Reveals an Unexpected Role for p110Î² in Early Adaptive Responses to p110Î±-Specific Inhibitors in Luminal Breast Cancer. Cancer Cell, 2015, 27, 97-108.	7.7	165
66	Bioprinting for cancer research. Trends in Biotechnology, 2015, 33, 504-513.	4.9	313
67	Chemopreventive effects of aspirin at a glance. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 254-263.	3.3	26
68	Light-Triggered, Self-Immolative Nucleic Acid-Drug Nanostructures. Journal of the American Chemical Society, 2015, 137, 6112-6115.	6.6	179
69	Role of Phosphoinositide 3-OH Kinase p110Î² in Skeletal Myogenesis. Molecular and Cellular Biology, 2015, 35, 1182-1196.	1.1	21
70	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell, 2015, 163, 174-186.	13.5	346
71	A PI3K p110Î²â€“Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nature Communications, 2015, 6, 8501.	5.8	44
72	The ERÎ±-PI3K Cascade in Proopiomelanocortin Progenitor Neurons Regulates Feeding and Glucose Balance in Female Mice. Endocrinology, 2015, 156, 4474-4491.	1.4	33

#	Article	IF	Citations
73	PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nature Reviews Cancer, 2015, 15, 7-24.	12.8	1,083
74	Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. ELife, 2015, 4, .	2.8	79
75	MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. ELife, 2014, 3, e01763.	2.8	104
76	Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110Î±. Journal of Clinical Investigation, 2014, 124, 1794-1809.	3.9	48
77	PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 6395-6400.	3.3	66
78	Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology, 2014, 16, 1080-1091.	4.6	124
79	The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome. Cell Cycle, 2013, 12, 3589-3593.	1.3	3
80	Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention. Cancer Discovery, 2013, 3, 44-51.	7.7	47
81	Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. Genes and Development, 2013, 27, 1568-1580.	2.7	19
82	Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies. , 2013, , .		0
83	Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110Î² as a Potential Anticancer Agent. Cancer Discovery, 2012, 2, 425-433.	7.7	152
84	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. Journal of Biological Chemistry, 2012, 287, 9742-9752.	1.6	89
85	The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes and Development, 2012, 26, 1573-1586.	2.7	116
86	The p110alpha and p110delta Isoforms of PI3 Kinase Are Dispensable for Hematopoietic Stem Cell Self-Renewal but Have Redundant Roles in B Cell Differentiation.. Blood, 2012, 120, 2322-2322.	0.6	0
87	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathwayâ€“dependent and PI3K pathwayâ€“independent mechanisms. Nature Medicine, 2011, 17, 1116-1120.	15.2	231
88	The Acute Effects of Leptin Require PI3K Signaling in the Hypothalamic Ventral Premammillary Nucleus. Journal of Neuroscience, 2011, 31, 13147-13156.	1.7	66
89	Specific Roles of the p110Î± Isoform of Phosphatidylinsositol 3-Kinase in Hepatic Insulin Signaling and Metabolic Regulation. Cell Metabolism, 2010, 11, 220-230.	7.2	119
90	PI3K Signaling in the Ventromedial Hypothalamic Nucleus Is Required for Normal Energy Homeostasis. Cell Metabolism, 2010, 12, 88-95.	7.2	96

#	Article	IF	Citations
91	Phosphatidyl Inositol 3-Kinase Signaling in Hypothalamic Proopiomelanocortin Neurons Contributes to the Regulation of Glucose Homeostasis. Endocrinology, 2009, 150, 4874-4882.	1.4	82
92	Estrogen Receptorâ€“Negative Breast Cancer: New Insights into Subclassification and Targeting. Clinical Cancer Research, 2009, 15, 6309-6310.	3.2	2
93	Should individual PI3 kinase isoforms be targeted in cancer?. Current Opinion in Cell Biology, 2009, 21, 199-208.	2.6	106
94	Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 2009, 8, 627-644.	21.5	2,218
95	The p110Î± Catalytic Isoform of PI3 Kinase Is Important for Erythropoiesis, but Has a Minimal Role in Hematopoietic Stem Cell Self-Renewal.. Blood, 2009, 114, 3620-3620.	0.6	0
96	Essential roles of PI(3)Kâ€“p110Î² in cell growth, metabolism and tumorigenesis. Nature, 2008, 454, 776-779.	13.7	654
97	The p110Î± Isoform of Phosphatidylinositol 3-Kinase Is Essential for Polyomavirus Middle T Antigen-Mediated Transformation. Journal of Virology, 2007, 81, 7069-7076.	1.5	28
98	Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene. Cell, 2007, 129, 1065-1079.	13.5	538
99	PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target. Science's STKE: Signal Transduction Knowledge Environment, 2006, 2006, pe52-pe52.	4.1	36
100	The p110Â isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16296-16300.	3.3	201
101	The oncogenic properties of mutant p110Â and p110Â phosphatidylinositol 3-kinases in human mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18443-18448.	3.3	313
102	Functional genetics and experimental models of human cancer. Trends in Molecular Medicine, 2004, 10, 344-350.	3.5	56
103	Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell, 2003, 3, 483-495.	7.7	262